169 related articles for article (PubMed ID: 18077530)
1. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting.
Goldenberg DM; Rossi EA; Sharkey RM; McBride WJ; Chang CH
J Nucl Med; 2008 Jan; 49(1):158-63. PubMed ID: 18077530
[TBL] [Abstract][Full Text] [Related]
2. The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity.
Chang CH; Rossi EA; Goldenberg DM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5586s-5591s. PubMed ID: 17875793
[TBL] [Abstract][Full Text] [Related]
3. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting.
Rossi EA; Goldenberg DM; Cardillo TM; McBride WJ; Sharkey RM; Chang CH
Proc Natl Acad Sci U S A; 2006 May; 103(18):6841-6. PubMed ID: 16636283
[TBL] [Abstract][Full Text] [Related]
4. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
[TBL] [Abstract][Full Text] [Related]
5. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.
Sharkey RM; Karacay H; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
Cancer Res; 2008 Jul; 68(13):5282-90. PubMed ID: 18593929
[TBL] [Abstract][Full Text] [Related]
6. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
McBride WJ; Zanzonico P; Sharkey RM; Norén C; Karacay H; Rossi EA; Losman MJ; Brard PY; Chang CH; Larson SM; Goldenberg DM
J Nucl Med; 2006 Oct; 47(10):1678-88. PubMed ID: 17015905
[TBL] [Abstract][Full Text] [Related]
7. A new method to produce monoPEGylated dimeric cytokines shown with human interferon-α2b.
Chang CH; Rossi EA; Cardillo TM; Nordstrom DL; McBride WJ; Goldenberg DM
Bioconjug Chem; 2009 Oct; 20(10):1899-907. PubMed ID: 19736932
[TBL] [Abstract][Full Text] [Related]
8. A universal pretargeting system for cancer detection and therapy using bispecific antibody.
Sharkey RM; McBride WJ; Karacay H; Chang K; Griffiths GL; Hansen HJ; Goldenberg DM
Cancer Res; 2003 Jan; 63(2):354-63. PubMed ID: 12543788
[TBL] [Abstract][Full Text] [Related]
9. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
Kraeber-Bodéré F; Faibre-Chauvet A; Saï-Maurel C; Gautherot E; Fiche M; Campion L; Le Boterff J; Barbet J; Chatal JF; Thédrez P
J Nucl Med; 1999 Jan; 40(1):198-204. PubMed ID: 9935077
[TBL] [Abstract][Full Text] [Related]
10. Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates.
Griffiths GL; Chang CH; McBride WJ; Rossi EA; Sheerin A; Tejada GR; Karacay H; Sharkey RM; Horak ID; Hansen HJ; Goldenberg DM
J Nucl Med; 2004 Jan; 45(1):30-9. PubMed ID: 14734668
[TBL] [Abstract][Full Text] [Related]
11. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody.
Sharkey RM; Cardillo TM; Rossi EA; Chang CH; Karacay H; McBride WJ; Hansen HJ; Horak ID; Goldenberg DM
Nat Med; 2005 Nov; 11(11):1250-5. PubMed ID: 16258537
[TBL] [Abstract][Full Text] [Related]
12. Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody.
Gautherot E; Kraeber-Bodéré F; Daniel L; Fiche M; Rouvier E; Saï-Maurel C; Thedrez P; Chatal JF; Barbet J
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3177s-3182s. PubMed ID: 10541361
[TBL] [Abstract][Full Text] [Related]
13. Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten.
Gautherot E; Bouhou J; Le Doussal JM; Manetti C; Martin M; Rouvier E; Barbet J
Cancer; 1997 Dec; 80(12 Suppl):2618-23. PubMed ID: 9406716
[TBL] [Abstract][Full Text] [Related]
14. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
Gold DV; Goldenberg DM; Karacay H; Rossi EA; Chang CH; Cardillo TM; McBride WJ; Sharkey RM
Cancer Res; 2008 Jun; 68(12):4819-26. PubMed ID: 18559529
[TBL] [Abstract][Full Text] [Related]
15. Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten.
Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Faivre-Chauvet A; Gautherot E; Barbet J; Chatal JF
J Nucl Med; 1999 Jul; 40(7):1216-21. PubMed ID: 10405144
[TBL] [Abstract][Full Text] [Related]
16. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
Cardillo TM; Karacay H; Goldenberg DM; Yeldell D; Chang CH; Modrak DE; Sharkey RM; Gold DV
Clin Cancer Res; 2004 May; 10(10):3552-61. PubMed ID: 15161715
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft.
Karacay H; Brard PY; Sharkey RM; Chang CH; Rossi EA; McBride WJ; Ragland DR; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Nov; 11(21):7879-85. PubMed ID: 16278412
[TBL] [Abstract][Full Text] [Related]
18. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
Moosmayer D; Berndorff D; Chang CH; Sharkey RM; Rother A; Borkowski S; Rossi EA; McBride WJ; Cardillo TM; Goldenberg DM; Dinkelborg LM
Clin Cancer Res; 2006 Sep; 12(18):5587-95. PubMed ID: 17000696
[TBL] [Abstract][Full Text] [Related]
19. Structure-based bacteriophage screening for AKAP-selective PKA regulatory subunit variants.
Walker-Gray R; Gold MG
Methods Mol Biol; 2015; 1294():167-80. PubMed ID: 25783885
[TBL] [Abstract][Full Text] [Related]
20. Improved tumor targeting with chemically cross-linked recombinant antibody fragments.
King DJ; Turner A; Farnsworth AP; Adair JR; Owens RJ; Pedley RB; Baldock D; Proudfoot KA; Lawson AD; Beeley NR
Cancer Res; 1994 Dec; 54(23):6176-85. PubMed ID: 7954464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]